- Home
- POLE vs CRDF Comparison
POLE vs CRDF Comparison
Compare POLE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLE
- CRDF
- Stock Information
- Founded
- POLE 2024
- CRDF 1999
- Country
- POLE United States
- CRDF United States
- Employees
- POLE N/A
- CRDF N/A
- Industry
- POLE
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- POLE
- CRDF Health Care
- Exchange
- POLE NYSE
- CRDF Nasdaq
- Market Cap
- POLE 299.8M
- CRDF 233.5M
- IPO Year
- POLE 2024
- CRDF N/A
- Fundamental
- Price
- POLE $10.39
- CRDF $4.15
- Analyst Decision
- POLE
- CRDF Strong Buy
- Analyst Count
- POLE 0
- CRDF 6
- Target Price
- POLE N/A
- CRDF $11.92
- AVG Volume (30 Days)
- POLE 10.3K
- CRDF 1.4M
- Earning Date
- POLE 01-01-0001
- CRDF 08-07-2025
- Dividend Yield
- POLE N/A
- CRDF N/A
- EPS Growth
- POLE N/A
- CRDF N/A
- EPS
- POLE N/A
- CRDF N/A
- Revenue
- POLE N/A
- CRDF $587,000.00
- Revenue This Year
- POLE N/A
- CRDF N/A
- Revenue Next Year
- POLE N/A
- CRDF N/A
- P/E Ratio
- POLE $58.70
- CRDF N/A
- Revenue Growth
- POLE N/A
- CRDF N/A
- 52 Week Low
- POLE $9.94
- CRDF $2.01
- 52 Week High
- POLE $11.16
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- POLE N/A
- CRDF 68.00
- Support Level
- POLE N/A
- CRDF $3.07
- Resistance Level
- POLE N/A
- CRDF $4.24
- Average True Range (ATR)
- POLE 0.00
- CRDF 0.21
- MACD
- POLE 0.00
- CRDF 0.07
- Stochastic Oscillator
- POLE 0.00
- CRDF 95.76
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.